Plendil
Plendil Price range: $ 13,00 through $ 267,00
Back to products
Podowart
Podowart Price range: $ 66,00 through $ 190,00

Pletal

Price range: $ 41,00 through $ 434,00

Pletal is a highly effective medication containing cilost

Active substance: Cilostazol
SKU: Pletal Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Pletal (Cilostazol): A Detailed Reference Guide

Pletal belongs to a class of pharmacological agents known as phosphodiesterase III inhibitors with antiplatelet and vasodilatory properties. It is an FDA-approved prescription medication indicated to increase maximal walking distance in patients experiencing intermittent claudication. Because Pletal requires careful cardiovascular evaluation prior to initiation, it is dispensed strictly under prescription in accordance with federal and state regulations.

Intermittent claudication manifests as painful muscular cramping in the legs during physical exertion due to inadequate peripheral arterial blood flow. By inhibiting platelet aggregation and dilating blood vessels in the lower limbs, Pletal helps alleviate exertional ischemic leg pain. Clinical management requires adherence to dosing schedules and continuous monitoring by a healthcare professional.

Parameter Clinical Specification
Active Ingredient Cilostazol
Therapeutic Class Phosphodiesterase III Inhibitor / Antiplatelet Agent
Dosage Form Oral Tablet (50 mg, 100 mg)
Route of Administration Oral
Prescription Status Prescription (Rx) Only
Primary Purpose Reduction of symptoms of intermittent claudication

1. Indications and Mechanism of Action

Approved Medical Indications: Pletal is indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increase in pain-free and maximal walking distance in patients with peripheral arterial disease. It is not intended as a substitute for surgical revascularization or direct arterial interventions. Any off-label use–such as secondary prevention of non-cardioembolic stroke or treatment of Raynaud’s phenomenon–lacks primary FDA indication for those specific uses and requires individualized specialist evaluation.

Pharmacological Mechanism of Action: Pletal and several of its metabolites reversibly inhibit the enzyme phosphodiesterase type 3 (PDE3). This inhibition suppresses cyclic adenosine monophosphate (cAMP) degradation, leading to elevated intracellular cAMP concentrations in blood platelets and vascular smooth muscle cells. Increased cAMP levels prevent platelet activation and aggregation while inducing direct relaxation and vasodilation of peripheral arterial beds, particularly in the femoral vascular tree. Additionally, cilostazol inhibits vascular smooth muscle cell proliferation in response to injury.

What to Expect Upon Initiating Therapy: Symptom improvement following the initiation of Pletal is gradual rather than immediate. Patients usually observe initial enhancements in walking distance within 2 to 4 weeks after starting treatment. However, full therapeutic response may require up to 12 weeks of continuous compliance at the recommended daily dosage.

Evaluating Therapeutic Response: Response to treatment is routinely assessed by measuring treadmill walking distance or monitoring changes in daily ambulatory limits. If no measurable benefit is observed after 12 weeks of consistent administration, a physician may re-evaluate the risk-benefit profile of continuing therapy.

2. Pharmacokinetics and Dosing Guidelines

Absorption and Pharmacokinetic Profile: Following oral administration, cilostazol is absorbed through the gastrointestinal tract. Absolute bioavailability is not precisely quantified, but ingestion with high-fat meals significantly increases absorption, raising peak plasma concentrations (Cmax) by approximately 90% and area under the curve (AUC) by 25%. Cilostazol is 95% to 98% bound to plasma proteins, primarily albumin. It undergoes extensive hepatic metabolism via the cytochrome P450 enzyme system, predominantly CYP3A4 and to a lesser extent CYP2C19. Two major active metabolites are produced: 3,4-dehydro-cilostazol (which accounts for a significant portion of PDE3 inhibition) and 4′-trans-hydroxy-cilostazol. The apparent elimination half-life of cilostazol and its active metabolites is approximately 11 to 13 hours. Approximately 74% of the dose is excreted via urine and 20% via feces as inactive metabolic products.

Dosing Schedule and Administration: The standard adult dosage of Pletal is 100 mg administered orally twice daily. Doses should be taken at least 30 minutes before or 2 hours after breakfast and dinner. Taking Pletal with food alters its absorption kinetics and increases systemic exposure, which can heighten the frequency of adverse effects.

Dosage Adjustments for Drug-Drug Interactions: A reduced dosage of 50 mg twice daily is recommended when Pletal is co-administered with potent inhibitors of CYP3A4 (such as ketoconazole, itraconazole, or erythromycin) or CYP2C19 (such as omeprazole). Patients with moderate to severe renal impairment or hepatic impairment require clinical evaluation prior to initiating dosing adjustments.

Missed Dose Instructions: If a scheduled dose is missed, it should be skipped, and the regular dosing schedule resumed at the next planned time. Patients must not double the dose to compensate for a missed administration.

Safety Profile, Contraindications, and FAQ

3. Warnings, Precautions, and Drug Interactions

Black Box Warning and Heart Failure Contraindication: Pletal bears an FDA Boxed Warning regarding its use in patients with heart failure. Cilostazol and several of its active metabolites are phosphodiesterase III inhibitors. Other PDE3 inhibitors (such as milrinone or amrinone) have demonstrated decreased overall survival rates in patients suffering from Class III–IV congestive heart failure. Consequently, Pletal is strictly contraindicated in patients with heart failure of any severity.

Adverse Reactions and Side Effects: The most frequently reported adverse effects associated with Pletal during controlled trials include headache, diarrhea, abnormal stools, palpitations, dizziness, and rhinitis. Headaches are often transient but may persist in some individuals. Serious cardiovascular side effects include ventricular tachycardia, angina pectoris, and severe hypotension. Hematologic reactions such as thrombocytopenia, leukopenia, or agranulocytosis occur rarely and necessitate immediate clinical monitoring.

Drug Interaction Profile: Co-administration of Pletal with strong or moderate inhibitors of CYP3A4 (e.g., diltiazem, erythromycin, ketoconazole) or CYP2C19 (e.g., omeprazole) increases systemic exposure to cilostazol and its active metabolites, increasing the risk of adverse effects. Concomitant use with other antiplatelet agents (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, direct oral anticoagulants) may exert an additive effect on bleeding risk. Daily consumption of grapefruit juice should be avoided as it inhibits intestinal CYP3A4 and increases peak cilostazol concentrations.

Food and Alcohol Considerations: High-fat food significantly enhances drug absorption, requiring administration strictly on an empty stomach. Consumption of alcohol during therapy may produce additive vasodilatory effects, contributing to dizziness, flushing, or orthostatic hypotension.

Special Populations: Safe use during pregnancy (Pregnancy Category C) and lactation has not been established. Cilostazol is excreted in animal milk; decision must be made whether to discontinue nursing or discontinue the drug. Use in pediatric populations under 18 years of age has not been studied. Elderly patients demonstrate no significant differences in safety or efficacy compared to younger adults, though individual sensitivity must be considered.

Severe Symptom (Red Flag) Immediate Action Required
Signs of Heart Failure: Rapid weight gain, swelling in feet/ankles, worsening shortness of breath. Discontinue use immediately and contact emergency medical services.
Cardiovascular Symptoms: Severe chest pain, irregular or racing heartbeat (tachycardia). Seek urgent emergency room evaluation.
Unusual Bleeding: Persistent nosebleeds, blood in urine or stool, unexpected bruising. Seek prompt clinical attention and evaluate coagulation profile.
Severe Allergic Reaction: Facial or tongue swelling, rash, difficulty swallowing or breathing. Obtain immediate emergency medical care.

4. Frequently Asked Questions

Can Pletal be taken together with aspirin or blood thinners?

Pletal can interact with other antiplatelet drugs and anticoagulants. Taking Pletal alongside medications such as aspirin, clopidogrel, or warfarin increases the overall risk of bleeding. Combined therapy requires strict oversight and risk assessment by the prescribing physician.

Why is it necessary to take Pletal on an empty stomach?

Ingesting Pletal with food–especially meals high in fat–significantly increases the amount of drug absorbed into the bloodstream. This rapid increase in systemic concentration elevates the frequency and severity of side effects such as severe headaches and palpitations. Therefore, it must be taken at least 30 minutes before or 2 hours after meals.

What should be done if headaches occur after starting Pletal?

Headache is one of the most common reported side effects, resulting from the vasodilatory effects of phosphodiesterase III inhibition. While headaches often diminish over the first few weeks of therapy, persistent or severe headaches should be reported to a healthcare provider for management options or dosage evaluation.

Is Pletal safe for patients with a history of heart failure?

No. Pletal is explicitly contraindicated in patients with heart failure of any severity due to an FDA Boxed Warning. Studies on related phosphodiesterase III inhibitors showed reduced survival rates in patients with heart failure.

How long is Pletal therapy typically continued?

Pletal is prescribed as a long-term management option for intermittent claudication. The duration of therapy depends on clinical efficacy, patient tolerance, and ongoing evaluation of peripheral vascular health by the prescribing clinician.

This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.

Additional information
Dosage

50mg

,

100mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία